	Substit	ute for form 1449A/	PTO			Complete if Known	
					Application Number	09/724,406	
	INF	ORMATIO	N DI	SCLOSURE	Filing Date	11/28/2000	
OIPE	STA	ATEMENT	BY A	PPLICANT	First Named Inventor	Francisco et al.	
/O· · · ·	20				Art Unit	1642	
	2084	(use as many s	sheets a	s necessary)	Examiner Name	Misook Yu	
DEC 3 O 700	Speet	1	of	2	Attorney Docket Number	9632-006-999	
,	F/						

			U.S. PATENT DO	CUMENTS+	
Examiner	Cite No.	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
tnitials*	No.				Figures Appear
my		US 2004-0018194 A1	01-29-2004	Francisco et al.	
<u> </u>		US 2005-0123536 A1	06-09-2005	Law et al.	
		<u> </u>			
			·		
			· ·	<u> </u>	
				 	

				FOREIGN PA	TENT DOCUME	ENTS		
Examiner Cite	For	eign Patent Doc	ument	Dahlination Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant		
Initials*	No.¹	Country Code ³	Number ⁴	Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	Τ⁰
248		wo	97/17374		05-15-1997	Medac Gesellschaft	Pages 18-23	
4		wo	05/001038	A2	01-06-2005	Seattle Genetics		1

Examiner Signature	misor	<u> </u>	Date Considered	3- 30 -06	
-----------------------	-------	----------	--------------------	-----------	--

EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at www.uspio.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precade the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Subatituta.	for form 1	440P/PTO			O					
Substitute	igrigim 1	449B/PTO		Application Number	Complete if Known					
INFO	RMA'	TION DIS	CLOSURE	Filing Date	10/983,340 November 5, 2904					
STAT	EME	NT BY A	PPLICANT	First Named Inventor	Doronina, Svetlana O.					
				Art Unit	1614					
ſı	use as m	any sheets as	e nacassarv)	Examiner Name		─ // ,				
Sheet	2	of	2	Attorney Docket Number	Unassigned 018891-001020US 0					
					Wrong of	11 U 3 0 b				
				NT LITERATURE DOCUME		/)]				
Examiner Initials *	Cite No.1	Include na (book, r	magazine, journal, ser	CAPITAL LETTERS), title of the arti rial, symposium, catalog, etc.), date blisher, city and/or country where p	icle (when appropriate), title of the item a, page(s), volume issue number(s), published.	T ²				
			ences Results (2 pages	<u> </u>						
		BARTLETT Refractory or 1403.	et al., "Phase I Study or Recurrent CD30 + Ho	of SGN-30, a Chimeric Monoclonal ematologic Malignancies," <u>BLOOD</u>	Antibody (mAb), in Patients with Vol. 100(11), December, 2002, Abs					
		Safety, Antito Antibody) in Abs 2390.	umor Activity and Pha Patients with Refracto	rmacokinetics of Six Weekly Doses bry or Recurrent CD30+ Hematolog	of SGN-30 (anti-CD30 Monoclonal ic Malignancies," <u>BLOOD</u> 102(11), 2003,					
		CERVENY e anti-CD30 m	CERVENY et al., "Hodgkin's disease growth inhibition and sepsitization to standard chemotherapeutics by the anti-CD30 monoclonal antibody SGN-30," PROC AM ASSOC CANCER RES vol. 45, March 2004, Abs 2258.							
		CERVENY e	et al., "Signaling via th eutics," <u>LEUKEMIA</u>	anti-CD30 mAb SGX-30 sensitizes Hodgkin's disease cells to conventional 0:1648-1655 (2005).						
		CERVENY e Sensitizes Ce	et al., "The Anti-CD30 ells to Established Che	Monoclonal Anylbody SGN-30 Inh motherapeutics," <u>BLOOD</u> 104(11),	ibits Hodgkins Disease Growth and 2004, Abs 2639					
		KABAT et al	l., Sequences of Protei	ns of Immunological Interest, 5th E	d., NIH Publication No. 91-3242, pp. xv-					
·		KOON et al.,	, "Anti-CD30 antibody	based therapy," <u>CURRENT OPIN</u>	sed therapy," CURRENT OPINION IN ONCOLOGY 12:588-593 (2000)					
		LEONARD e Antibody SG	et al., "Targeting CD30 N-30," PROC AM SO	as Therapy for Hodgkin's Disease CCLIN ONCOL April 2005, Abs 2	. Phase II Results with the Monoclonal 2553					
		LEONARD of Recurrent Ho	et al., "Phase II Study o xdgkin's Diseaso," <u>BL</u>	of SGN-30 (Anti-CD30 Monoclonal DOD 104(11) 2004, Abs 2635.	Antibody) in Patients with Refractory or					
		WAHL et al., vitro and affe	, "The anti-CD30 monets antitumor activity	oclonal antibody SGN-30 promotes in models of Hodgkin's disease," <u>C/</u>	growth arrest and DNA fragmentation in ANCER RES. 62:3736-3742 (2002).					
,										
			10	nuentry, aut uniferial no in no	t, docket grahen re of these matches applicate. my 4-3.	-06				
Examiner Signature	1/			Date Considered						

EXAMINER: Injuist if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's únique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

MAR 1 3 7006 Sub

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

neet		or	/	1
		A	7 4-	3-06

	Complete if Known	
Application Number	09/724,406	
Filing Date	11/28/2000	
First Named Inventor	Francisco et al.	
Art Unit	1642	
Examiner Name	Misook Yu	
Attorney Docket Number	9632-006-999	

			U.S. PATENT DO	CUMENTS+	
		Document Number			
Examiner Initials*	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ry		US 2003-0186384 A1	10-02-2003	Barth et al.	
		· · · · · · · · · · · · · · · · · · ·		<u> </u>	
			<u> </u>	 	
			7 11 11 11 11 11 11 11 11 11 11 11 11 11		
					
			-		

			[OREIGN PA	TENT DOCUM	ENTS	, <u> </u>	
		For	eign Patent Docur	ment		N	Pages, Columns, Lines,	
Examiner Cite Initials* No.		Country Code ³ Number ⁴ Kind Code ³ (if known) Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T®			
my		wo	91/07437	A2	05-30-1991	Parker, et al		
		wo	01/80880	A2	11-01-2001	Barth, et al		
		DE	19543039	Cl	11-21-1996	Medac Gesellschaft		一

Examiner Signature	Misooh	7	Date Considered	3-30-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

60497666 v1

Express Mail No.: <u>EL 477 035 523 US</u> Sheet <u>1</u> of <u>1</u>

Sheet<u>1</u> of <u>1</u>

						ATTY, DOCKET NO.		APPLICATION NO.			
IPF						9632-006-999 09/724,406					
∕ o∵ 7	ısfà	F REFERENCES CITE	D BY APPLIC	ANT		APPLICANT					
	•	(Use several sheets if no				Francisco et al.					
MAR 1 8	Mar S					FILING DATE		GROUP			
						November 28, 2000		1642			
TRAD	ENLI		U.S	. PATENT	DOCUM	IENTS					
*EXAMINER	l 1 l				NAME	CLASS	SUBCLASS	FILING IF APPR	DATE OPRIATE		
INITIAL	*										
			FORE	IGN PATE	NT DOC	UMENTS					
	DOCUMENT NUMBER DATE				COUNTRY	CLASS	SUBCLASS	TRANSLATION			
									YES	NO	
_											
	L	OTHER RE	FERENCES (In	cludina Au	thor, Tit	le, Date, Pertinent Pages, Etc.)					
MX	вм		unotherapy of	Human 1	Fumors	with T-Cell-activating Bispe	ecific Ar	ntibodies: (Stimul	lation	
	BN	Poblet al 1993 "CD3	30-Antigen-Sp Against CD3	ecific Ta	raetina	and Activation of T Cells Vitential Use for the Treatmen	a Murir t of Hoo	ne Bispecif Igkin's Lyn	ic nphon	na,"	
	во		:huh, 1995, "T	fumor Th	erapy l	by Immune Recruitment with	Bispe	cific Antob	odies,	HE(
								置	રુ	出	
								- 20	ठा	मा	
EXAMINER		nion 2			DATE	CONSIDERED 3-20-	06	1600/290	2 902	VEO	
*EXAMINE	R; Initia	al if reference considered, whand not considered. Include	nether or not cita copy of this form	ntion is in co	onforma commu	nce with MPEP 609; Draw line th	rough cil	•			

Sheet 1 of 1 Express Mail No.: EV 335 857 168 US APPLICATION NO. ATTY DOCKET NO. 09/724,406 9632-006 CONFIRMATION NO. LIST OF REFERENCES CITED BY APPLICANT APPLICANT 7578 (Use several sheets if necessary) FRANCISCO et al. GROUPECEIVED FILING DATE 1642 November 28, 2000 U.S. PATENT DOCUMENTS FILING DATE PI 600/2800 CLASS *EXAMINER NAME DATE DOCUMENT NUMBER INITIAL FOREIGN PATENT DOCUMENTS TRANSLATION SUBCLASS CLASS COUNTRY DATE DOCUMENT NUMBER OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) Pohl et al., "CD30-Specific AB1-AB2-AB3 Internal Image Antibody Network: Potential Use as Anti- \overline{BP} Idiotype Vaccine Against Hodgkin's Lymphoma," Int. J. Cancer 54:418-425 (1993) my Weigert et al., "Rearrangement of Genetic Information May Produce Immunoglobulin Diversity," BQ Nature 276:785-790 (1978) 3-20-06 DATE CONSIDERED **EXAMINER** • EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.